Literature DB >> 34148165

Hepcidin in Kawasaki disease: upregulation by acute inflammation in patients having resistance to intravenous immunoglobulin therapy.

Takashi Ishikawa1,2, Yasuyuki Wada1,3, Hiroyuki Namba1,3, Toshinao Kawai4,5.   

Abstract

Hepcidin is an iron metabolism inhibitor that increases with chronic inflammation. However, it is unclear whether hepcidin indicates acute inflammatory response in Kawasaki disease (KD), which is an acute systemic vasculitis. In this study, we examined the serum hepcidin levels before and after intravenous immunoglobulin (IVIG) therapy in responders and non-responders to IVIG. This was a pilot prospective observational study at a university hospital. All KD patients were initially administered 2 g/kg of IVIG as the first IVIG therapy (IVIG1) on day 4 to day 7 after onset. Non-responders to IVIG1 were additionally treated with the second IVIG therapy (IVIG2) using 1 g/kg of IVIG. All KD patients were also treated with aspirin. We measured serum hepcidin levels before IVIG1, after IVIG1, and during the recovery period. Among the 31 KD patients, 21 patients and 5 patients improved after IVIG1 (responders-1) and IVIG2 (responders-2), respectively, but 5 patients did not improve after IVIG2 (non-responders). Serum hepcidin levels before IVIG1 were significantly higher in responders-2 (159.0 ng/mL) and non-responders (240.0 ng/mL), compared to responders-1 (103.0 ng/mL). Serum hepcidin levels after IVIG1 were significantly higher in non-responders (163.0 ng/mL), compared to responders-1 (43.4 ng/mL) and responders-2 (54.6 ng/mL). Serum hepcidin levels of non-responders to IVIG were higher before IVIG and remained high after IVIG. Erythrocyte-related indexes, including hemoglobin, reticulocytes, iron, and ferritin before IVIG1, were not significantly different among the three groups. Serum hepcidin might be excessively upregulated by acute inflammation in KD patients having resistance to IVIG. Key Points • Hepcidin, an iron metabolism inhibitor in chronic inflammation, increases during the acute phase of Kawasaki disease. • Hepcidin levels before IVIG of non-responders were higher than those of responders in Kawasaki disease. • Hepcidin might be excessively upregulated by acute inflammation in KD patients having resistance to IVIG.

Entities:  

Keywords:  Anemia; IVIG; Inflammatory marker; KD; Prediction; Refractory

Year:  2021        PMID: 34148165     DOI: 10.1007/s10067-021-05822-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  23 in total

1.  Orchestration of iron homeostasis.

Authors:  Robert E Fleming; Bruce R Bacon
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

2.  Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease.

Authors:  Tohru Kobayashi; Yoshinari Inoue; Kazuo Takeuchi; Yasunori Okada; Kazushi Tamura; Takeshi Tomomasa; Tomio Kobayashi; Akihiro Morikawa
Journal:  Circulation       Date:  2006-05-30       Impact factor: 29.690

Review 3.  Anemia of inflammation.

Authors:  Guenter Weiss; Tomas Ganz; Lawrence T Goodnough
Journal:  Blood       Date:  2018-11-06       Impact factor: 22.113

4.  Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment.

Authors:  Tetsuya Sano; Shunji Kurotobi; Kouji Matsuzaki; Takehisa Yamamoto; Ichiro Maki; Kazunori Miki; Shigetoyo Kogaki; Junichi Hara
Journal:  Eur J Pediatr       Date:  2006-08-01       Impact factor: 3.183

5.  The Combined Usefulness of the Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in Predicting Intravenous Immunoglobulin Resistance with Kawasaki Disease.

Authors:  Yoichi Kawamura; Seiichiro Takeshita; Takashi Kanai; Yusuke Yoshida; Shigeaki Nonoyama
Journal:  J Pediatr       Date:  2016-08-12       Impact factor: 4.406

6.  Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease.

Authors:  Kimiyasu Egami; Hiromi Muta; Masahiro Ishii; Kenji Suda; Yoko Sugahara; Motofumi Iemura; Toyojiro Matsuishi
Journal:  J Pediatr       Date:  2006-08       Impact factor: 4.406

7.  A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan.

Authors:  T Kawasaki; F Kosaki; S Okawa; I Shigematsu; H Yanagawa
Journal:  Pediatrics       Date:  1974-09       Impact factor: 7.124

Review 8.  Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Scientific Statement for Health Professionals From the American Heart Association.

Authors:  Brian W McCrindle; Anne H Rowley; Jane W Newburger; Jane C Burns; Anne F Bolger; Michael Gewitz; Annette L Baker; Mary Anne Jackson; Masato Takahashi; Pinak B Shah; Tohru Kobayashi; Mei-Hwan Wu; Tsutomu T Saji; Elfriede Pahl
Journal:  Circulation       Date:  2017-03-29       Impact factor: 29.690

9.  Resistance to intravenous immunoglobulin in children with Kawasaki disease.

Authors:  Adriana H Tremoulet; Brookie M Best; Sungchan Song; Susan Wang; Elena Corinaldesi; Julia R Eichenfield; Danielle D Martin; Jane W Newburger; Jane C Burns
Journal:  J Pediatr       Date:  2008-03-04       Impact factor: 4.406

Review 10.  Hepcidin regulation in the anemia of inflammation.

Authors:  Chia-Yu Wang; Jodie L Babitt
Journal:  Curr Opin Hematol       Date:  2016-05       Impact factor: 3.284

View more
  1 in total

1.  Combination of Hemoglobin-for-Age Z-Score and Plasma Hepcidin Identified as a Novel Predictor for Kawasaki Disease.

Authors:  Ya-Ling Yang; Ho-Chang Kuo; Kuang-Den Chen; Chi-Hsiang Chu; Kuang-Che Kuo; Mindy Ming-Huey Guo; Ling-Sai Chang; Ying-Hsien Huang
Journal:  Children (Basel)       Date:  2022-06-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.